Opportunity Information: Apply for PAR 07 446
Apply for PAR 07 446
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.839 Blood Diseases and Resources Research 93.855 Allergy, Immunology and Transplantation Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Oct 15, 2009 and posted on Sep 7, 2007.
- Applicants must submit their applications by May 7, 2010 Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) Special district governments County governments For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) State governments Private institutions of higher education Public and State controlled institutions of higher education Small businesses City or township governments.
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH grant opportunity "Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)" (Funding Opportunity Number PAR-07-446) is designed to back early-stage, high-impact research projects that could open up new directions in understanding and treating primary immunodeficiency diseases. The focus is on innovative, exploratory or developmental studies rather than large, fully mature research programs. The science priorities center on ex vivo work using human specimens as well as studies using existing or newly developed animal models. The announcement also highlights interest in novel clinical strategies that improve how these diseases are detected, help identify their molecular causes, or lead to genuinely new therapeutic approaches.
This FOA uses the NIH R21 mechanism, which is intended for projects that are more conceptual and higher risk than a typical R01, but still grounded in a clear rationale and a feasible plan. It is paired with a parallel announcement of the same scientific scope that uses the R03 mechanism (PAR-07-447), giving applicants a smaller-grant option depending on the scale and maturity of the idea. A notable point in the description is that investigators who have not previously held independent NIH funding, or who have not previously been independently funded in this specific field, are explicitly encouraged to apply. That emphasis signals an intent to bring newer investigators and fresh perspectives into primary immunodeficiency research.
In terms of funding expectations, NIH anticipated approximately $1.1 million total available for this FOA and projected making about 3 to 4 new awards, assuming enough high-quality applications are received and appropriated funds remain available. The project period is capped at two years, consistent with the R21 program’s role as a short, exploratory award. Budget limits are also clearly defined: applicants may request up to $275,000 in direct costs across the two-year period, with a maximum of $200,000 in direct costs allowed in any single year. The FOA specifies no cost-sharing or matching requirement.
Eligibility is broad and includes many types of organizations. Academic institutions (public/state-controlled and private), nonprofit organizations (with or without 501(c)(3) status), small businesses and other for-profit organizations (other than small businesses), and a range of government entities are all eligible. The eligibility list also extends to U.S. territories and possessions, tribal governments (both federally recognized and other than federally recognized), and tribally designated organizations. The FOA explicitly permits foreign (non-U.S.) entities to apply and notes that eligible federal agencies can apply as well. It also includes mission-focused institution types such as Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and Alaska Native and Native Hawaiian-serving institutions, along with faith-based and community-based organizations. In short, NIH structured this opportunity so that a wide set of research settings can compete, including those that may have unique patient populations, specimen resources, or translational capabilities.
For who can lead the project, the FOA states that any individual with the skills, knowledge, and resources to carry out the work may serve as Project Director/Principal Investigator, working through their institution. NIH also reiterates its standing encouragement for applications from individuals from underrepresented racial and ethnic groups and individuals with disabilities. The announcement allows multiple PDs/PIs on a single application, which can be useful for multidisciplinary projects that combine, for example, clinical immunology, genetics, and model development.
There are several important application rules and limitations. The R21 under this FOA is not renewable, meaning you cannot submit a competing renewal (formerly called a competing continuation) to extend the same project beyond the two-year limit. If an application is not funded initially, up to two resubmissions of a previously reviewed R21 application are allowed. Another restriction is that an applicant may serve as PD/PI on only one application per receipt date for this FOA. However, a single institution may submit multiple applications as long as each proposal is scientifically distinct.
Administratively, this opportunity is categorized as a discretionary grant in the Health domain and is associated with CFDA numbers 93.839 (Blood Diseases and Resources Research), 93.855 (Allergy, Immunology and Transplantation Research), and 93.865 (Child Health and Human Development Extramural Research). It was posted on September 7, 2007, and used multiple receipt dates, with the listed current closing date in the provided record being May 7, 2010, and an archive date of June 7, 2010. The sponsoring agency is the National Institutes of Health, and the full announcement was hosted through the NIH grants guide at the provided link.
FAQs: NIH PAR-07-446 - Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)
What is this funding opportunity?
This is a National Institutes of Health (NIH) funding opportunity titled "Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)" with Funding Opportunity Number (FON) PAR-07-446. It supports early-stage, high-impact research intended to open new directions in understanding and treating primary immunodeficiency diseases.
What type of research is this FOA trying to support?
The FOA emphasizes innovative, exploratory, or developmental projects rather than large, fully mature research programs. It is aimed at studies that are higher risk and more conceptual than a typical R01, but still based on a clear rationale and feasible plan.
What scientific areas are highlighted as priorities?
The described science priorities include: (1) ex vivo work using human specimens, (2) studies using existing or newly developed animal models, and (3) novel clinical strategies that improve detection of primary immunodeficiency diseases, identify molecular causes, or enable genuinely new therapeutic approaches.
What NIH grant mechanism is used for this opportunity?
This FOA uses the NIH R21 mechanism, which is designed for short, exploratory/developmental research projects that can be more conceptual and higher risk than standard research project grants.
Is there a smaller-grant option related to this same topic?
Yes. The announcement notes a parallel funding opportunity with the same scientific scope that uses the R03 mechanism (PAR-07-447). That provides a smaller-grant option depending on the scale and maturity of the proposed idea.
How much total funding did NIH anticipate making available under this FOA?
NIH anticipated approximately $1.1 million total available for this FOA, assuming sufficient high-quality applications are received and appropriated funds are available.
How many awards did NIH expect to make?
The FOA projected about 3 to 4 new awards.
What is the maximum project period?
The project period is capped at two years, consistent with the R21 mechanism’s role as a short, exploratory award.
What are the budget limits for an R21 under this FOA?
Applicants may request up to $275,000 in direct costs across the two-year period, with no more than $200,000 in direct costs allowed in any single year.
Is cost sharing or matching required?
No. The FOA specifies that there is no cost-sharing or matching requirement.
Who is eligible to apply (organizational eligibility)?
Eligibility is broad. The FOA lists eligible organizations including academic institutions (public/state-controlled and private), nonprofit organizations (with or without 501(c)(3) status), small businesses, and other for-profit organizations (other than small businesses), as well as government entities. It also includes U.S. territories and possessions, tribal governments (federally recognized and other than federally recognized), and tribally designated organizations.
Are foreign (non-U.S.) organizations allowed to apply?
Yes. The FOA explicitly permits foreign (non-U.S.) entities to apply.
Can federal agencies apply?
Yes. The FOA notes that eligible federal agencies can apply.
Are mission-focused institution types and community organizations included in eligibility?
Yes. The FOA explicitly includes institution types such as Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and Alaska Native and Native Hawaiian-serving institutions. It also mentions faith-based and community-based organizations as eligible.
Who can serve as the Project Director/Principal Investigator (PD/PI)?
The FOA states that any individual with the skills, knowledge, and resources to carry out the proposed work may serve as PD/PI, working through their institution.
Does the FOA encourage applications from specific investigator groups?
Yes. Investigators who have not previously held independent NIH funding, or who have not previously been independently funded in this specific field, are explicitly encouraged to apply. NIH also reiterates encouragement for applications from individuals from underrepresented racial and ethnic groups and individuals with disabilities.
Are multiple PDs/PIs allowed on one application?
Yes. The announcement allows multiple PDs/PIs on a single application, which can support multidisciplinary approaches (for example, combining clinical immunology, genetics, and animal model development).
Can this R21 be renewed to extend the project beyond two years?
No. The FOA states that the R21 under this announcement is not renewable, meaning a competing renewal cannot be submitted to extend the same project beyond the two-year limit.
If an application is not funded, how many resubmissions are allowed?
Up to two resubmissions of a previously reviewed R21 application are allowed if the application is not funded initially.
How many applications can a single PD/PI submit per receipt date under this FOA?
An applicant may serve as PD/PI on only one application per receipt date for this FOA.
Can an institution submit more than one application?
Yes. A single institution may submit multiple applications as long as each proposal is scientifically distinct.
How is this opportunity categorized administratively?
The opportunity is categorized as a discretionary grant in the Health domain and is associated with CFDA numbers 93.839 (Blood Diseases and Resources Research), 93.855 (Allergy, Immunology and Transplantation Research), and 93.865 (Child Health and Human Development Extramural Research).
Who is the sponsoring agency?
The sponsoring agency is the National Institutes of Health (NIH).
When was this FOA posted, and what dates are listed for closing and archiving?
The FOA was posted on September 7, 2007. The provided record lists a current closing date of May 7, 2010, and an archive date of June 7, 2010.
Where was the full announcement hosted?
The full announcement was hosted through the NIH grants guide at the link referenced in the record for PAR-07-446.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R03)
Previous opportunity: Interdisciplinary Research on Implantation (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 07 446
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 07 446) also looked into and applied for these:
| Funding Opportunity |
|---|
| Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R03) Apply for PAR 07 447 Funding Number: PAR 07 447 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Role of Adipose Tissue as an Endocrine Organ in Reproduction and Infertility (R01) Apply for PA 08 059 Funding Number: PA 08 059 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Role of Adipose Tissue as an Endocrine Organ in Reproduction and Infertility (R21) Apply for PA 08 060 Funding Number: PA 08 060 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Extramural Associates Research Development Award (EARDA) (G11) Apply for PAR 08 096 Funding Number: PAR 08 096 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Mechanisms of Functional Recovery After Stroke (R01) Apply for PA 08 099 Funding Number: PA 08 099 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Mechanisms of Functional Recovery After Stroke (R21) Apply for PA 08 100 Funding Number: PA 08 100 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Leiomyomata Uteri Basic Science, Translational and Clinical Research (R01) Apply for PAR 08 102 Funding Number: PAR 08 102 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Adverse Outcomes of Assisted Reproductive Technologies (R01) Apply for PA 08 104 Funding Number: PA 08 104 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Investigations on Primary Immunodeficiency Diseases (R01) Apply for PAR 08 206 Funding Number: PAR 08 206 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Biosocial Approaches to Infertility Research (R21) Apply for PA 09 032 Funding Number: PA 09 032 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Womens Reproductive Health Research (WRHR) Career Development Program (K12) Apply for RFA HD 08 014 Funding Number: RFA HD 08 014 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $440,000 |
| Population Research Infrastructure Program Short term Support for Rising Programs (R24) Apply for PAR 07 401 Funding Number: PAR 07 401 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Collaborative Pediatric Critical Care Research Network (U10) Apply for RFA HD 08 025 Funding Number: RFA HD 08 025 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Postdoctoral Research Training for Obstetricians and Gynecologists (T32) Apply for PAR 09 049 Funding Number: PAR 09 049 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Obstetric Pharmacology Research Units (U10) Apply for RFA HD 09 002 Funding Number: RFA HD 09 002 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $650,000 |
| Advanced Neural Prosthetics Research and Development (U01) Apply for PA 09 063 Funding Number: PA 09 063 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Enhancing Developmental Biology Research at Undergraduate Institutions Academic Research Enhancement Award (R15) Apply for PAR 09 084 Funding Number: PAR 09 084 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Advanced Tools and Technologies for Deep Brain Stimulation in Movement Disorders SBIR (R43/R44) Apply for PA 07 396 Funding Number: PA 07 396 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Academic Community Partnership Conference Series (U13) Apply for PAR 09 092 Funding Number: PAR 09 092 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $30,000 |
| Childhood Obesity Prevention and Treatment Research Consortium (U01) Apply for RFA HL 10 004 Funding Number: RFA HL 10 004 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 07 446", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.